Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 77Multiple Myeloma 40Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma 37Lymphoma, Non-Hodgkin 27Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 18Burkitt Lymphoma 18Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 17Neoplasms, Plasma Cell 16Lymphoma, B-Cell 16Leukemia, Myeloid, Acute 16Neuroblastoma 12Hodgkin Disease 12Lymphoma, Large-Cell, Immunoblastic 11Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 9Lymphoma, B-Cell, Marginal Zone 9Inflammatory Breast Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Ovarian Neoplasms 8Immunoblastic Lymphadenopathy 7Neoplasm Metastasis 6Melanoma 6Leukemia, Myeloid, Chronic-Phase 6Hematologic Neoplasms 6

Interventions

pegfilgrastim 1NPI 2358 1Granulocyte Colony-Stimulating Factor 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Chemotherapy-induced Neutropenia × Cyclophosphamide × Clear all
NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡